We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $105M invested in Lineage Cell Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
2,925% more call options, than puts
Call options by funds: $121K | Put options by funds: $4K
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
37% more capital invested
Capital invested by funds: $76.2M → $105M (+$28.4M)
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
8% more funds holding
Funds holding: 106 → 115 (+9)
2.64% more ownership
Funds ownership: 38.32% → 40.96% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Holders
115
Holders Change
+9
Holders Change %
+8.49%
% of All Funds
1.83%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
24
Increased
26
Reduced
21
Closed
13
Calls
$121K
Puts
$4K
Net Calls
+$117K
Net Calls Change
+$38K
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.01M |
| 2 |
Millennium Management
New York
|
+$1.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$897K |
| 4 |
Jane Street
New York
|
+$635K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$555K |
Top Sellers
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$237K |
| 2 |
E
Ergoteles
New York
|
-$220K |
| 3 |
Man Group
London,
United Kingdom
|
-$143K |
| 4 |
Lazard Asset Management
New York
|
-$107K |
| 5 |
BlackRock
New York
|
-$104K |
